Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Ogwang, Caroline, Afolabi, Muhammed, Kimani, Domtila, Jagne, Ya Jankey, Sheehy, Susanne H, Bliss, Carly M, Duncan, Christopher J A, Collins, Katharine A, Garcia Knight, Miguel A, Kimani, Eva, Anagnostou, Nicholas A, Berrie, Eleanor, Moyle, Sarah, Gilbert, Sarah C, Spencer, Alexandra J, Soipei, Peninah, Mueller, Jenny, Okebe, Joseph, Colloca, Stefano, Cortese, Riccardo, Viebig, Nicola K, Roberts, Rachel, Gantlett, Katherine, Lawrie, Alison M, Nicosia, Alfredo, Imoukhuede, Egeruan B, Bejon, Philip, Urban, Britta ORCID: https://orcid.org/0000-0002-4197-8393, Flanagan, Katie L, Ewer, Katie J, Chilengi, Roma, Hill, Adrian V S and Bojang, Kalifa (2013) 'Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.'. PLoS ONE, Vol 8, Issue 3, e57726.

Preview

Text PLoS_ONE_8_3_e57726.pdf - Published Version Available under License Creative Commons Attribution. Download (865kB)

Abstract

BACKGROUND

Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naïve adults following controlled human malaria infection (CHMI).

METHODOLOGY

We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns.

RESULTS

ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC).

CONCLUSIONS

ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.

Item Type:	Article
Subjects:	QW Microbiology and Immunology > Immunotherapy and Hypersensitivity > QW 805 Vaccines. Antitoxins. Toxoids QX Parasitology > Protozoa > QX 135 Plasmodia WA Public Health > Preventive Medicine > WA 115 Immunization WA Public Health > Health Problems of Special Population Groups > WA 395 Health in developing countries WC Communicable Diseases > Tropical and Parasitic Diseases > WC 750 Malaria
Faculty: Department:	Biological Sciences > Department of Tropical Disease Biology
Digital Object Identifer (DOI):	https://doi.org/10.1371/journal.pone.0057726
Depositing User:	Mary Creegan
Date Deposited:	14 Aug 2014 11:38
Last Modified:	06 Feb 2018 13:07
URI:	https://archive.lstmed.ac.uk/id/eprint/3841

Statistics

View details

Actions (login required)

Edit Item